Ignite Creation Date:
2024-05-06 @ 3:53 PM
Last Modification Date:
2024-10-26 @ 1:59 PM
Study NCT ID:
NCT04799990
Status:
WITHDRAWN
Last Update Posted:
2022-12-09
First Post:
2021-03-15
Brief Title:
Study to Assess Adverse Events When Subcutaneous Risankizumab Injection is Given to Adult Participants With Psoriasis in Real World Setting
Sponsor:
AbbVie
Organization:
AbbVie
Study Overview
Official Title:
Post-Marketing Real World Safety Study of Risankizumab in the United States
Status:
WITHDRAWN
Status Verified Date:
2022-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Study is not recruiting and using secondary data sources only
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Study is not recruiting and using secondary data sources only
Detailed Description:
Study is not recruiting and using secondary data sources only
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?:
None